Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism CLEC5A inhibitors(C-type lectin domain containing 5A inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Preclinical | China | 29 Apr 2026 |






